Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“therapy—often used in patients with clinical evidence of cardiovascular disease and/or insulin resistance—may also result in significant weight gain,fluid retention, and ahigher risk of heart failure [57].”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 2×
“Endocrinol Metab, [23] Diabetes, [24,27] Eur J Clin Endocrinol, [25] and J Clin Invest [26].”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 3×
“Approximately 10% to 16% of individuals treated with exenatide reported diarrhea, [61,62] as did approximately 8% to 19% of patients treated with liraglutide [71,81].”
BackgroundInfluentialBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 2×
“Impaired insulin secretion [1,48,49] and β-cell dysfunction, [50] insulin resistance, obesity, and an impaired incretin effect [30] all play a role in the pathogenesis andprogression of type 2 diabetes (Figure 2).”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · cited 1×
“GLP-1, exenatide, and liraglutide have been reported to exert beneficial effects on β-cell function (insulin secretion) and (in animal studies) β-cell mass—perhaps by prevention of cell loss through apoptosis (cell death) and by promotion of β-cell growth [89-92].”
BackgroundStandards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Five stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“The once-weekly formulation was associated with lower rates of nausea—the most common adverse effect seen with GLP-1 receptor agonists [66,69].”
BackgroundSelf-citationOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065 · cited 1×
“Traditional therapies have also been associated with significant weight gain [11] and an increased risk for hypoglycemia [12].”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 2×
“Endocrinol Metab, [23] Diabetes, [24,27] Eur J Clin Endocrinol, [25] and J Clin Invest [26].”
BackgroundAschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823 · cited 1×
“Both sulfonylurea and insulin therapy are associated with significant weight gain and risk of hypoglycemia [56].”
BackgroundMarre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807 · cited 1×
“Impaired insulin secretion [1,48,49] and β-cell dysfunction, [50] insulin resistance, obesity, and an impaired incretin effect [30] all play a role in the pathogenesis andprogression of type 2 diabetes (Figure 2).”
BackgroundHeine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762 · cited 1×
“Early, aggressive intervention is nowknown to exert a “legacy effect,” even years after patients have opted out of intensive therapy protocols, fostering a sustained reduction in the risk of bothmicro- and macrovascular complications [33,34].”
BackgroundThe barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725 · cited 1×
“Traditional therapies have also been associated with significant weight gain [11] and an increased risk for hypoglycemia [12].”
BackgroundKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 2×
“8 kg; 2and 3-year extension data [64,79] demonstrated aweight reduction of approximately 5 kg.”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 1×
“, glycemic control agents that directly benefit the heart and the vascularity) [51-53].”
BackgroundGlycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648 · cited 1×
“Koro and colleagues [17] have reported a decline in the percentage of patients with diabetes who are able to achieve HbA1c target on a broad array of therapies—from 44.”
BackgroundImprovements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988–2002
Saaddine, J. B., Cadwell, B., Gregg, E. W., Engelgau, M. M., Vinicor, F., Imperatore, G., & Narayan, K. M. V. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00005 · Cited by 571 · cited 1×
“More recently, Saaddine and colleagues [18] analyzed NHANES data (1988 to 1994 and 1999 to 2002), as well as Behavioral Risk Factor Surveillance System data and found that over the past decade the proportion of patients with poor glycemic control declined slightly (by ∼ 4%) but nonsignificantly.”
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567 · cited 1×
“Impaired insulin secretion [1,48,49] and β-cell dysfunction, [50] insulin resistance, obesity, and an impaired incretin effect [30] all play a role in the pathogenesis andprogression of type 2 diabetes (Figure 2).”
BackgroundFerrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 1×
“β-Cell impairment is now recognized to arise and worsen years before the onset of diabetes and its initial manifestation of postprandial hyperglycemia [29].”
BackgroundHermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“Liraglutide is 97% homologous to native GLP-1, with a single amino acid substitution extending its half-life to 13 hours [70].”
BackgroundGoldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 1×
“GLP-1, exenatide, and liraglutide have been reported to exert beneficial effects on β-cell function (insulin secretion) and (in animal studies) β-cell mass—perhaps by prevention of cell loss through apoptosis (cell death) and by promotion of β-cell growth [89-92].”
BackgroundIs Glycemic Control Improving in U.S. Adults?
Hoerger, T. J., Segel, J. E., Gregg, E. W., & Saaddine, J. B. (2008) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457 · cited 1×
“This class of agents includes twice-daily exenatide, originally derived from the salivary glands of the Gila monster, which has 53% homology with human GLP-1 [59].”
BackgroundBosi, E., Camisasca, R. P., Collober, C., Rochotte, E., & Garber, A. J. (2007) · Diabetes Care · doi:10.2337/dc06-1732 · Cited by 447
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R., & Trautmann, M. (2007) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 437 · cited 1×
“The once-weekly formulation was associated with lower rates of nausea—the most common adverse effect seen with GLP-1 receptor agonists [66,69].”
BackgroundDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · cited 1×
“However, measures of β-cell function (homeostasis model assessment [HOMA]–B and HOMA-IR) are improved in the setting of both exenatide and liraglutide treatment [61,93-97].”
BackgroundKennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416 · cited 2×
“In open-label observational studies, exenatide therapy has been associated with improved triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and apolipoprotein B levels [84].”
BackgroundSelf-citationLactic Acidosis in Patients with Diabetes Treated with Metformin
Misbin, R. I., Green, L., Stadel, B. V., Gueriguian, J. L., Gubbi, A., & Fleming, G. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380415 · Cited by 403 · cited 1×
“Moreover, patients with impaired renal function and a history of heart failure are not appropriate candidates for metformin treatment [54,55].”
BackgroundDeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373 · cited 2×
“Comparative data assessing the relative effects of exenatide versus sitagliptin on postprandial blood glucose [118] suggest that GLP-1 receptor agonists (perhaps due to higher mealtime concentrations of exenatide versus the levels of native GLP-1 achieved with sitagliptin) have a greater effect on postprandial glucose…”
BackgroundUse of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355 · cited 1×
“Newer concerns about thiazolidinediones and bone fractures have also been reported [58].”
BackgroundToskes, P. P. (1990) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00513-6 · Cited by 339
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.009 · Cited by 312 · cited 2×
“8 kg) [114-117].”
BackgroundAhrén, B., Pacini, G., Foley, J. E., & Schweizer, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1936 · Cited by 309
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 1×
“However, measures of β-cell function (homeostasis model assessment [HOMA]–B and HOMA-IR) are improved in the setting of both exenatide and liraglutide treatment [61,93-97].”
BackgroundZinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279 · cited 1×
“8 kg; 2and 3-year extension data [64,79] demonstrated aweight reduction of approximately 5 kg.”
BackgroundRosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Buteau, J., Foisy, S., Rhodes, C. J., Carpenter, L., Biden, T. J., & Prentki, M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2237 · Cited by 252 · cited 1×
“GLP-1, exenatide, and liraglutide have been reported to exert beneficial effects on β-cell function (insulin secretion) and (in animal studies) β-cell mass—perhaps by prevention of cell loss through apoptosis (cell death) and by promotion of β-cell growth [89-92].”
BackgroundRistic, S., Byiers, S., Foley, J., & Holmes, D. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00539.x · Cited by 248 · cited 1×
“DPP-4 inhibitor therapy has demonstrated a low dropout rate in large clinical trials; therefore good patient adherence may be expected [111,123].”
BackgroundBalas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., He, Y.-L., Darland, C., Holst, J. J., Deacon, C. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1882 · Cited by 243 · cited 1×
“Modest improvements in measures of β-cell secretory function have been reported for both sitagliptin [110,119] and vildagliptin, [120-122] although the long-term clinical implications of these improvements have not been determined.”
BackgroundBarnett, A. H., Burger, J., Johns, D., Brodows, R., Kendall, D. M., Roberts, A., & Trautmann, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.006 · Cited by 239
Self-citationMeier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230 · cited 2×
“Endocrinol Metab, [23] Diabetes, [24,27] Eur J Clin Endocrinol, [25] and J Clin Invest [26].”
BackgroundEffect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 215
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Improvement in Diabetes Care of Underinsured Patients Enrolled in Project Dulce
Philis-Tsimikas, A., Walker, C., Rivard, L., Talavera, G., Reimann, J. O. F., Salmon, M., & Araujo, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.110 · Cited by 208
Chang, A. M., Jakobsen, G., Sturis, J., Smith, M. J., Bloem, C. J., An, B., Galecki, A., & Halter, J. B. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1786 · Cited by 207
Does Diabetes Disease Management Save Money and Improve Outcomes?
Sidorov, J., Shull, R., Tomcavage, J., Girolami, S., Lawton, N., & Harris, R. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.684 · Cited by 205
Cook, M. N., Girman, C. J., Stein, P. P., & Alexander, C. M. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02078.x · Cited by 197
Ryskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 181 · cited 2×
“Endocrinol Metab, [23] Diabetes, [24,27] Eur J Clin Endocrinol, [25] and J Clin Invest [26].”
BackgroundUnraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Rosenstock, J., Foley, J. E., Rendell, M., Landin-Olsson, M., Holst, J. J., Deacon, C. F., Rochotte, E., & Baron, M. A. (2008) · Diabetes Care · doi:10.2337/dc07-1616 · Cited by 153
Rith-Najarian, S. J., Branchaud, C., Beaulieu, O., Gohdes, D., Simonson, G., & Mazze, R. (1998) · PubMed · Cited by 148
Gallstones and diabetes: A case-control study in a free-living population sample
De Santis, A., Attili, A. F., Corradini, S. G., Scafato, E., Cantagalli, A., De Luca, C., Pinto, G., Lisi, D., & Capocaccia, L. (1997) · Hepatology · doi:10.1002/hep.510250401 · Cited by 144
Long-term follow-up evaluation of blood glucose awareness training
Cox, D. J., Gonder-Frederick, L., Julian, D. M., & Clarke, W. (1994) · Diabetes Care · doi:10.2337/diacare.17.1.1 · Cited by 143
Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin
Viswanathan, P., Chaudhuri, A., Bhatia, R., Al-Atrash, F., Mohanty, P., & Dandona, P. (2007) · Endocrine Practice · doi:10.4158/ep.13.5.444 · Cited by 142 · cited 1×
“Use of exenatide enabled a reduction in insulin dose and was associated with weight loss [76].”
BackgroundBrazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., & Stein, P. P. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00691.x · Cited by 138 · cited 1×
“Modest improvements in measures of β-cell secretory function have been reported for both sitagliptin [110,119] and vildagliptin, [120-122] although the long-term clinical implications of these improvements have not been determined.”
BackgroundReinventing Type 2 Diabetes: Pathogenesis, Treatment, and Prevention
Unger, R. H. (2008) · JAMA · doi:10.1001/jama.299.10.1185 · Cited by 120 · cited 1×
“Build-up of ectopic fat in those tissues ultimately induces insulin resistance, β-cell lipotoxicity, and diminished β-cell function, leading to metabolically inadequate insulin secretion [3].”
BackgroundNauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M., & Balena, R. (2009) · Diabetes Care · doi:10.2337/dc08-1961 · Cited by 117 · cited 1×
“Taspoglutide (a once-weekly formulation of a human GLP-1 analog) and albiglutide (an albumin conjugated GLP-1 analog) are in earlier stages of clinical development [74,75].”
BackgroundRoad Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus
Jellinger, P. S., Davidson, J. A., Blonde, L., EINHORN, D. F., Grunberger, G., Handelsman, Y., Hellman, R., Lebovitz, H. E., Levy, P., & Roberts, V. L. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.260 · Cited by 104
Davis, S. N., Johns, D., Maggs, D. G., Xu, H., Northrup, J., & Brodows, R. G. (2007) · Diabetes Care · doi:10.2337/dc06-2532 · Cited by 101
Obesity and Treatment of Diabetes With Glyburide May Both Be Risk Factors for Acute Pancreatitis
Blomgren, K. B., Sundström, A., Steineck, G., & Wiholm, B. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.298 · Cited by 101 · cited 1×
“, obesity, sulfonylurea use, [104] gallstones, [105] and hypertriglyceridemia [106]) are also associated with type 2 diabetes and its treatment.”
BackgroundExecutive Summary: Standards of Medical Care in Diabetes—2009
(2008) · Diabetes Care · doi:10.2337/dc09-s006 · Cited by 93
Mari, A., Scherbaum, W. A., Nilsson, P. M., Lalanne, G., Schweizer, A., Dunning, B. E., Jauffret, S., & Foley, J. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1639 · Cited by 88 · cited 1×
“Modest improvements in measures of β-cell secretory function have been reported for both sitagliptin [110,119] and vildagliptin, [120-122] although the long-term clinical implications of these improvements have not been determined.”
BackgroundMari, A., Degn, K., Brock, B., Rungby, J., Ferrannini, E., & Schmitz, O. (2007) · Diabetes Care · doi:10.2337/dc07-0310 · Cited by 84
Disease management for diabetes mellitus: impact on hemoglobin A1c.
Sidorov, J. E., Gabbay, R. A., Harris, R. J., Shull, R., Girolami, S., Tomcavage, J. F., Starkey, R., & Hughes, R. (2000) · PubMed · Cited by 81
Weight changes following the initiation of new anti‐hyperglycaemic therapies
Nichols, G. A., & Gomez‐Caminero, A. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00580.x · Cited by 67
Staged diabetes management. Toward an integrated model of diabetes care.
Mazze, R. S., Etzwiler, D. D., Strock, E. S., PETERSON, K. A., Mcclave, C. R., Meszaros, J. F., Leigh, C., Owens, L. W., Deeb, L. C., & Peterson, A. E. (1994) · PubMed · Cited by 66
Non-Insulin Antidiabetic Therapy in Cardiac Patients: Current Problems and Future Prospects
Fisman, E. Z., Motro, M., & Tenenbaum, A. (2008) · Advances in cardiology · doi:10.1159/000115193 · Cited by 65 · cited 1×
“Moreover, patients with impaired renal function and a history of heart failure are not appropriate candidates for metformin treatment [54,55].”
BackgroundGlycemic response to newly initiated diabetes therapies.
Karter, A. J., Moffet, H. H., Liu, J. Y., Parker, M. M., Ahmed, A. T., Go, A. S., & Selby, J. V. (2007) · PubMed · Cited by 63
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Gilbert, M. P., & Pratley, R. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.013 · Cited by 59
State of diabetes care in the United States.
Blonde, L. (2007) · PubMed · Cited by 52
Schmitz, O., Russell-Jones, D. L., Vaag, A. A., Sethi, B. K., Lalic, N. M., Antić, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2008) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(08)24116-x · Cited by 45
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 38 · cited 1×
“, glycemic control agents that directly benefit the heart and the vascularity) [51-53].”
BackgroundStaged Diabetes Management: A Systematic Approach
Mazze, R. S., Strock, E. S., Simonson, G. D., & Bergenstal, R. M. (2004) · Cited by 34
Self-citationINCREASED RISK OF ACUTE PANCREATITIS OBSERVED IN PATIENTS WITH TYPE 2 DIABETES
Noel, R. A., Braun, D. K., Patterson, R., & Bloomgren, G. (2008) · Pancreas · doi:10.1097/01.mpa.0000335350.81450.e9 · Cited by 26
Diabetes control with physical activity and exercise.
Castañeda, C. (2003) · PubMed · Cited by 24
Missing the Point: Substituting Exenatide for Nonoptimized Insulin
Rosenstock, J., & Fonseca, V. A. (2007) · Diabetes Care · doi:10.2337/dc07-1592 · Cited by 23
Yamagishi, S., Matsui, T., & Nakamura, K. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.05.039 · Cited by 23 · cited 1×
“Analyses of follow-up data from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions (DCCT/EDIC) and UKPDS, suggest that a kind of “metabolic memory” exists and may be associated with vascular damage not easily reversed even by effective treatment and subsequent good glycemic control [12…”
MethodBergenstal, R. M. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.98 · Cited by 19 · cited 5×
“Clinical use of the GLP-1 receptor agonists has—not surprisingly— been directed toward patients in need of additional blood glucose control and weight reduction (Figure 3) [38-47].”
BackgroundInfluentialSelf-citationUnmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents
Pitocco, D., Valle, D. D. L. N. M., Rossi, A., & Gentilella, R. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346373 · Cited by 14 · cited 1×
“Titration issues, side effects, and problems with patient adherence to therapy become magnified as agents are added [13,14].”
BackgroundThe Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions
Gallwitz, B. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.208 · Cited by 14 · cited 2×
“Publish defects in the development and progression of hyperglycemia in type 2 diabetes [1,2].”
BackgroundDoggrell, S. A. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.7.1011 · Cited by 11 · cited 1×
“10%) and physical activity for ≥30 minutes per day [7,8].”
BackgroundNichol, H., Retallack, J., & Panagiotopoulos, C. (2008) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(08)21008-7 · Cited by 11
Mazze, R. S., Powers, M. A., Wetzler, H. P., & Ofstead, C. L. (2008) · Population Health Management · doi:10.1089/pop.2008.0008 · Cited by 8 · cited 5×
“Clinical use of the GLP-1 receptor agonists has—not surprisingly— been directed toward patients in need of additional blood glucose control and weight reduction (Figure 3) [38-47].”
BackgroundInfluentialLoss of confidence in diabetes management.
Salber, P. R., Bestermann, W. H., Schwartz, S. S., & Marchetti, A. E. (2008) · PubMed · Cited by 2
Cited by
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Self-citationDiet and exercise in the prevention and treatment of type 2 diabetes mellitus
Magkos, F., Hjorth, M. F., & Astrup, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0381-5 · Cited by 469
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Fiehn, O., Garvey, W. T., Newman, J. W., Lok, K. H., Hoppel, C. L., & Adams, S. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015234 · Cited by 421
Metadata
- Authors
- Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 122
- Issue
- 6
- Pages
- S37-S50
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2017044017
- Cited by
- 176
- References
- 109
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.